Strides Pharma Science receives IR from USFDA for Ranitidine tablets

27 Sep 2019 Evaluate

Strides Pharma Science has received an Information Request (IR) from the US Food and Drug Administration (USFDA) to provide test data related to N-nitrosodimethylamine (NDMA) impurities in Ranitidine tablets. This data is to be provided to the agency in 30 days.

While the Company conducts the relevant tests mandated by the USFDA, it has suspended sales of ranitidine tablets in the US market until such time it has clarity of next steps as would be indicated by the USFDA. The Company predominantly sells Ranitidine tablets in the US markets, and its front end sales globally for the product were around $9 million in H1FY20.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.

Strides Pharma Scien Share Price

884.45 -2.65 (-0.30%)
11-Dec-2025 13:21 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1799.75
Dr. Reddys Lab 1274.70
Cipla 1509.75
Zydus Lifesciences 924.85
Lupin 2081.40
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×